Leave a request
An antibiotic used to treat a rare and deadly lung disease could be a lifesaver for adults with severe asthma, a ground-breaking Australian study has found.
The research team from the Hunter Medical Research Institute (HMRI) in New South Wales gave the drug azithromycin to 200 patients whose asthma could not be fully controlled with traditional medication.
After taking the antibiotic three times a week for nearly a year, the patients reported a 40 per cent reduction in moderate and severe asthma attacks.
"Many of them were surprised by the benefit. One lady told me she'd never felt this good before, and she'd had asthma for many, many years," study author Professor Peter Gibson said.
Azithromycin is an antibiotic with anti-inflammatory properties that was hailed as a miracle cure in the 1980s for the lung disease diffuse panbronchiolitis.
"It's a very rare disease that kills people. It's rare in Australia but is quite common in Japan," Professor Gibson said.
"They discovered in the 1980s that if you treat these patients with azithromycin, they live. The patient had to take it for a year, but it kills the disease."
HMRI has found the drug also reduces swelling in the lungs of asthma sufferers.
"The main problem in asthma is narrowing of the airways, and that's caused by muscle spasms and inflammation. Azithromycin appears to work on the swelling and the mucus part of the problem," Professor Gibson said.
The retired school teacher from Sydney has suffered from asthma since childhood, but in recent years she'd developed a persistent hacking cough that made exercise impossible.
"It was horrible to hear whenever I exerted myself, I would be coughing and it did restrict me. I had to sleep with a few pillows to reduce the coughing at night," she said.
After taking azithromycin for about a year, Mrs Widders' cough disappeared.
She no longer needs to take the antibiotic and has halved her traditional doses of asthma medication.
"I'm just so much more active. I walk up to 10 kilometres a day — quite challenging walks sometimes — and I feel fine," she said.
"I think it has improved me to that stage where I feel confident to do almost anything now."
The HMRI team is now working on ways to prevent antibiotic resistance in patients who take azithromycin.
"It can be done. We must be selective about the people for whom the treatment is given, and also monitor the potential side effects of the treatment," Professor Gibson said.
"We think there could be opportunity to develop different ways to give this antibiotic, for example, in shorter periods. Perhaps having a drug holiday, giving it in even lower doses."
Professor Gibson is also working with his team on an inhaled version of the drug, which would remove the antibiotic but still deliver the anti-inflammatory to the patient's lungs.
This material was created exclusively for WorldHealthNews project by Michael Kelly.
Leave a request